Marketing-authorisation holder
Biogen Inc.
15 medicines in 1 country, as authorisation holder and manufacturer.
Loading…
Marketing-authorisation holder
15 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
15 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADUHELM170mg/1.7ml (100mg/ml) | 300mg/3ml (100mg/ml) · Injectable | Aducanumab | United States | Marketed | 2021 |
| Avonex30mcg/0.5ml · Injection | Interferon beta-1a | United States | Marketed | 2012 |
| AVONEX1a 30ug/ml · Vial | Interferon beta-1a | United States | Marketed | 1996 |
| Avonex30mcg/0.5ml · Injection | Interferon beta-1a | United States | Marketed | 2003 |
| Plegridy94mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| Plegridy94mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| Plegridy63mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| Plegridy125mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| Plegridy63mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| SKYCLARYS50mg · Capsule | Omaveloxolone | United States | Marketed | 2023 |
| TECFIDERA120mg | 240mg · Capsule, delayed release | Dimethyl | United States | Marketed | 2013 |
| VUMERITY231mg · Capsule, delayed release | Diroximel fumarate | United States | Marketed | 2019 |
| ZINBRYTA150mg/ml · Injectable | Daclizumab | United States | Marketed | 2016 |
| ZURZUVAE20mg | 25mg | 30mg · Capsule | Zuranolone | United States | Marketed | 2023 |
| Zinbryta150mg/ml · Injection | Daclizumab | United States | Withdrawn | 2017 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 15 | 14 | 1 | CompaniesAll medicines |
Also in the registers of Colombia
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vencidos; source update 2026-09-16; acquired 2026-10-08.
Licence: CC BY-SA 4.0
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Keep Biogen Inc.’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callOther companies in the same group.